<p>Corvus Pharmaceuticals, Inc.（纳斯达克代码：CRVS - 获取免费报告）股票在周五达到了新的 52 周高点。该公司交易最高价为 9.38 美元，最后交易价为 9.1220 美元，成交量为 440382 股。该股票此前收盘价为 8.81 美元。</p>
<p>获取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
<h2>华尔街分析师观点</h2>
<p>CRVS 已成为多份分析师报告的主题。巴克莱在 10 月 13 日（星期一）的一份研究报告中开始覆盖 Corvus Pharmaceuticals。他们给予该公司的评级为 “增持”，目标价为 16.00 美元。瑞穗证券在 10 月 29 日（星期三）的一份研究报告中设定了 Corvus Pharmaceuticals 的目标价为 13.00 美元。韦斯评级在 10 月 8 日（星期三）的一份研究报告中重新发布了对 Corvus Pharmaceuticals 股票的 “卖出（d-）” 评级。最后，华尔街 Zen 在 11 月 8 日（星期六）的一份报告中将 Corvus Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。四位投资分析师对该股票给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，Corvus Pharmaceuticals 的平均评级为 “适度买入”，共识目标价为 14.25 美元。</p>
<p><strong>查看我们关于 Corvus Pharmaceuticals 的最新研究报告</strong></p>
<h2>Corvus Pharmaceuticals 价格表现</h2>
<p>该公司的市值为 6.8056 亿美元，市盈率为-17.09，贝塔值为 0.64。该公司的 50 日简单移动平均线为 7.84 美元，200 日简单移动平均线为 5.76 美元。</p>
<p>Corvus Pharmaceuticals（纳斯达克代码：CRVS - 获取免费报告）最近于 11 月 4 日（星期二）发布了其财报。该公司报告本季度每股收益为（0.12 美元），超过分析师一致预期的（0.14 美元）2 美分。平均而言，研究分析师预计 Corvus Pharmaceuticals, Inc. 本年度每股收益将为-0.63 美元。</p>
<h2>机构投资者对 Corvus Pharmaceuticals 的看法</h2>
<p>几家机构投资者最近买入和卖出了 CRVS 的股票。Quarry LP 在第三季度收购了价值约 27,000 美元的 Corvus Pharmaceuticals 新头寸。Jain Global LLC 在第三季度购买了价值约 204,000 美元的 Corvus Pharmaceuticals 新股份。Brevan Howard Capital Management LP 在第三季度收购了价值约 113,000 美元的 Corvus Pharmaceuticals 新头寸。美国银行在第三季度将其在 Corvus Pharmaceuticals 的持股增加了 14.5%。美国银行目前拥有该公司 151,966 股股票，价值 1,120,000 美元，此前在上个季度又购买了 19,237 股。最后，Creative Planning 在第三季度购买了价值约 186,000 美元的 Corvus Pharmaceuticals 新股份。目前 46.64% 的股票由机构投资者和对冲基金持有。</p>
<h2>关于 Corvus Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Corvus Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司，专注于开发和商业化免疫调节剂产品候选药物，以治疗实体癌症、T 细胞淋巴瘤、自身免疫性疾病、过敏性疾病和传染病。其主要产品候选药物是 soquelitinib（CPI-818），这是一种选择性共价抑制剂，针对白细胞介素 2 诱导的 T 细胞激酶（ITK），目前正在进行多中心的 1/1b 期临床试验，治疗外周 T 细胞淋巴瘤、实体肿瘤和特应性皮炎。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Corvus Pharmaceuticals</li>
<li>什么是便士股票？全面指南</li>
<li>Kroger 股票分析：数字转型、股息安全与 2026 年增长计划</li>
<li>如何计算投资回报率（ROI）</li>
<li>加密矿工会转向人工智能吗？关于三家关键参与者的最新消息</li>
<li>投资者必须了解的场外交易（OTC）股票</li>
<li>Salesforce 股票像弹簧一样蓄势待发，准备反弹</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Corvus Pharmaceuticals 吗？</h2>
<p>在考虑投资 Corvus Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Corvus Pharmaceuticals 并不在名单上。</p>
<p>虽然 Corvus Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Corvus制药

<p>Corvus 制药（NASDAQ:CRVS）达到了新的 52 周高点，交易价格高达 9.38 美元。分析师的评级各不相同，巴克莱给予 “增持” 评级和 16 美元的目标价，而韦斯评级则发布了 “卖出” 评级。该股票的共识评级为适度买入，目标价为 14.25 美元。机构投资者活跃，持股比例为 46.64%。Corvus 专注于针对各种疾病的免疫调节剂产品候选者</p>

<p>Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) shares reached a new 52-week high on Friday . The company traded as high as $9.38 and last traded at $9.1220, with a volume of 440382 shares trading hands. The stock had previously closed at $8.81.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc.（纳斯达克代码：CRVS - 获取免费报告）股票在周五达到了新的 52 周高点。该公司交易最高价为 9.38 美元，最后交易价为 9.1220 美元，成交量为 440382 股。该股票此前收盘价为 8.81 美元。</p>
</div><p>Get <strong>Corvus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>CRVS has been the subject of a number of analyst reports. Barclays initiated coverage on Corvus Pharmaceuticals in a research note on Monday, October 13th. They issued an &#34;overweight&#34; rating and a $16.00 price target for the company. Mizuho set a $13.00 price objective on Corvus Pharmaceuticals in a research note on Wednesday, October 29th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Corvus Pharmaceuticals in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Corvus Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, November 8th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Corvus Pharmaceuticals has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $14.25.</p>
<div class="lb-trans"><p>CRVS 已成为多份分析师报告的主题。巴克莱在 10 月 13 日（星期一）的一份研究报告中开始覆盖 Corvus Pharmaceuticals。他们给予该公司的评级为 “增持”，目标价为 16.00 美元。瑞穗证券在 10 月 29 日（星期三）的一份研究报告中设定了 Corvus Pharmaceuticals 的目标价为 13.00 美元。韦斯评级在 10 月 8 日（星期三）的一份研究报告中重新发布了对 Corvus Pharmaceuticals 股票的 “卖出（d-）” 评级。最后，华尔街 Zen 在 11 月 8 日（星期六）的一份报告中将 Corvus Pharmaceuticals 的评级从 “卖出” 上调至 “持有”。四位投资分析师对该股票给予了买入评级，一位给予了卖出评级。根据 MarketBeat 的数据，Corvus Pharmaceuticals 的平均评级为 “适度买入”，共识目标价为 14.25 美元。</p>
</div><p><strong>View Our Latest Research Report on Corvus Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Corvus Pharmaceuticals 的最新研究报告</strong></p>
</div><h2>Corvus Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 价格表现</h2>
</div><p>The firm has a market capitalization of $680.56 million, a PE ratio of -17.09 and a beta of 0.64. The business has a 50-day simple moving average of $7.84 and a 200-day simple moving average of $5.76.</p>
<div class="lb-trans"><p>该公司的市值为 6.8056 亿美元，市盈率为-17.09，贝塔值为 0.64。该公司的 50 日简单移动平均线为 7.84 美元，200 日简单移动平均线为 5.76 美元。</p>
</div><p>Corvus Pharmaceuticals (NASDAQ:CRVS - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. On average, research analysts expect that Corvus Pharmaceuticals, Inc. will post -0.63 earnings per share for the current year.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals（纳斯达克代码：CRVS - 获取免费报告）最近于 11 月 4 日（星期二）发布了其财报。该公司报告本季度每股收益为（0.12 美元），超过分析师一致预期的（0.14 美元）2 美分。平均而言，研究分析师预计 Corvus Pharmaceuticals, Inc. 本年度每股收益将为-0.63 美元。</p>
</div><h2>Institutional Investors Weigh In On Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Corvus Pharmaceuticals 的看法</h2>
</div><p>Several institutional investors have recently bought and sold shares of CRVS. Quarry LP acquired a new position in Corvus Pharmaceuticals during the 3rd quarter valued at about $27,000. Jain Global LLC purchased a new stake in shares of Corvus Pharmaceuticals during the third quarter worth about $204,000. Brevan Howard Capital Management LP acquired a new position in shares of Corvus Pharmaceuticals during the third quarter valued at about $113,000. Bank of America Corp DE boosted its stake in Corvus Pharmaceuticals by 14.5% in the 3rd quarter. Bank of America Corp DE now owns 151,966 shares of the company's stock worth $1,120,000 after purchasing an additional 19,237 shares in the last quarter. Finally, Creative Planning purchased a new stake in Corvus Pharmaceuticals during the 3rd quarter worth approximately $186,000. 46.64% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>几家机构投资者最近买入和卖出了 CRVS 的股票。Quarry LP 在第三季度收购了价值约 27,000 美元的 Corvus Pharmaceuticals 新头寸。Jain Global LLC 在第三季度购买了价值约 204,000 美元的 Corvus Pharmaceuticals 新股份。Brevan Howard Capital Management LP 在第三季度收购了价值约 113,000 美元的 Corvus Pharmaceuticals 新头寸。美国银行在第三季度将其在 Corvus Pharmaceuticals 的持股增加了 14.5%。美国银行目前拥有该公司 151,966 股股票，价值 1,120,000 美元，此前在上个季度又购买了 19,237 股。最后，Creative Planning 在第三季度购买了价值约 186,000 美元的 Corvus Pharmaceuticals 新股份。目前 46.64% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>About Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Corvus Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc. 是一家临床阶段的生物制药公司，专注于开发和商业化免疫调节剂产品候选药物，以治疗实体癌症、T 细胞淋巴瘤、自身免疫性疾病、过敏性疾病和传染病。其主要产品候选药物是 soquelitinib（CPI-818），这是一种选择性共价抑制剂，针对白细胞介素 2 诱导的 T 细胞激酶（ITK），目前正在进行多中心的 1/1b 期临床试验，治疗外周 T 细胞淋巴瘤、实体肿瘤和特应性皮炎。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Corvus Pharmaceuticals</li>
<li>What is a penny stock? A comprehensive guide</li>
<li>Kroger Stock Analysis: Digital Pivot, Dividend Safety &amp; 2026 Growth Plan</li>
<li>How to Calculate Return on Investment (ROI)</li>
<li>Will Crypto Miners Pivot to AI? Latest on 3 Key Players</li>
<li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li>
<li>Salesforce Stock Is Coiled Like a Spring and Ready to Rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Corvus Pharmaceuticals</li>
<li>什么是便士股票？全面指南</li>
<li>Kroger 股票分析：数字转型、股息安全与 2026 年增长计划</li>
<li>如何计算投资回报率（ROI）</li>
<li>加密矿工会转向人工智能吗？关于三家关键参与者的最新消息</li>
<li>投资者必须了解的场外交易（OTC）股票</li>
<li>Salesforce 股票像弹簧一样蓄势待发，准备反弹</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Corvus Pharmaceuticals 吗？</h2>
</div><p>Before you consider Corvus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Corvus Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前立即购买……而 Corvus Pharmaceuticals 并不在名单上。</p>
</div><p>While Corvus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Corvus Pharmaceuticals 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Corvus 制药（NASDAQ:CRVS）创下新的 12 个月高点 - 以下是发生的事情